Signe Korsgaard Skriver

4PUBLICATIONS

10CO-AUTHORS

Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Apr 17, 2026

Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapy.

|Aug 05, 2020

Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.

Signe Korsgaard Skriver, Maj-Britt Jensen, Jens-Ole Eriksen

|May 16, 2020

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.

Signe Korsgaard Skriver, Maj-Britt Jensen, Ann Soegaard Knoop

|Nov 24, 2017

Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).

Signe Korsgaard Skriver, Anne-Vibeke Laenkholm, Birgitte Bruun Rasmussen

Pageof 1

Frequent Collaborators

1 joint publications

Tove Filtenborg Tvedskov

1 joint publications

Anna Baech Slipsager

1 joint publications

Rana Bahij

1 joint publications

Heidi Søgaard Christensen

1 joint publications

Laura Vittrup Diness

1 joint publications

Birgitte Mayland Havelund

1 joint publications

Anne Ramlov

1 joint publications

Olga Tcacenco

1 joint publications

Christian Thomsen

1 joint publications

Laurids Østergaard Poulsen

Frequent Collaborators

1 joint publications

Tove Filtenborg Tvedskov

1 joint publications

Anna Baech Slipsager

1 joint publications

Rana Bahij

1 joint publications

Heidi Søgaard Christensen